A clinical trial is underway to compare ketamine and fentanyl for prehospital pain management in trauma patients.

A Phase 3 trial is underway to assess CAN-2409 immunotherapy combined with radiation for localized prostate cancer, aiming to improve disease-free survival.

Phase III trials show that combining immunotherapy drugs with chemotherapy improves survival in triple-negative breast cancer (TNBC) and muscle-invasive bladder cancer.

Bioxytran's antiviral compound PHM23 has been selected by the University of Georgia for inclusion in their grant submission to the USDA's $100 million Highly Pathogenic Avian Influenza Poultry Innovation Grand Challenge.

The University of Glasgow's Living Laboratory for Precision Medicine has partnered with myDNA to generate real-world evidence supporting pharmacogenomics adoption in healthcare systems.

University of Calgary researchers are initiating a validation study for the Mira Hormone Monitor, a device claiming to provide precise numerical readings of hormone biomarkers from urine samples.

A second University of Minnesota study has found that hydroxychloroquine, an anti-malaria drug once championed by President Donald Trump, does not provide substantial benefits in treating COVID-19. The study compared outcomes of patients taking hydroxychloroquine with those taking a placebo and found no significant differences in death rates, hospitalizations, or persistent symptoms. The findings add to the growing evidence against the use of hydroxychloroquine for COVID-19 treatment.

The University of Minnesota is conducting groundbreaking clinical trials for glioblastoma, an aggressive brain cancer, utilizing less invasive laser treatments, engineered viruses, and a drug that aids in tumor identification. These trials aim to directly target cancer cells, offering patients like Brian Braun a quicker recovery and improved quality of life. With glioblastoma affecting an estimated 24,000 people annually, these advancements represent a significant step forward in brain cancer treatment.

Kiromic BioPharma has activated the University of Arizona Cancer Center as the fifth clinical trial site for its Deltacel-01 Phase 1 trial.

University of Kentucky researchers are conducting the LiBBY Study to assess medical cannabis for managing agitation and discomfort in late-stage dementia patients.

A recent study identifies progesterone, specifically Provera, as a significant risk factor for vision loss related to meningiomas in premenopausal women.

Inimmune Corporation's INI-4001, a novel cancer treatment compound developed in collaboration with the University of Montana, is moving into human clinical trials in Australia.

Pembrolizumab combined with chemotherapy reduces recurrence risk and improves survival in high-risk, early-stage triple-negative breast cancer (TNBC).

Genprex has entered a sponsored research agreement with the University of Michigan to study Reqorsa® gene therapy combined with ALK-inhibitors for ALK+ lung cancer.

A University of Minnesota trial has concluded that hydroxychloroquine is no more effective than a placebo in preventing COVID-19 after exposure, with 40% of participants experiencing non-serious side effects.

4C Medical has begun enrolling patients in the ATLAS pivotal trial to assess the safety and efficacy of its AltaValve system for mitral regurgitation (MR).

The University of Hong Kong (HKU) and Gleneagles Hospital have opened a clinical trials centre to advance medical research and improve patient outcomes.

The Duchossois Family Institute (DFI) at UChicago is set to begin clinical trials in January to investigate rebuilding the gut microbiome in compromised patients.

Marshall University is conducting a clinical trial to assess oral lofexidine, a non-opioid medication, for treating Neonatal Opioid Withdrawal Syndrome (NOWS).

The EASi-KIDNEY trial will assess vicadrostat's efficacy in improving outcomes for chronic kidney disease (CKD) patients when combined with existing treatments.